DUMONTET; Charles

Patent Applications and Registrations

Patent applications and USPTO patent grants for DUMONTET; Charles.The latest application filed is for "liposomal formulation of bacterial lipopolysaccharide combined with a cytotoxic agent, and use thereof in anti-tumour therapy".

Company Profile

0.2.15

DUMONTET; Charles - Venissieux FR
Dumontet; Charles - Villeurbanne Cedex FR
DUMONTET; Charles - Lyon FR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Liposomal Formulation Of Bacterial Lipopolysaccharide Combined With A Cytotoxic Agent, And Use Thereof In Anti-tumour Therapy App 20210177755 - DUMONTET; Charles ; et al.	2021-06-17
Chalcone derivatives having an anti-allergic activity Grant 9,896,415 - Dumontet , et al. February 20, 2	2018-02-20
5'-nucleotidase inhibitors and therapeutic uses thereof Grant 9,783,541 - Chaloin , et al. October 10, 2	2017-10-10
Bispecific T cell activating antigen binding molecules App 20170114146 - Klein; Christian ; et al.	2017-04-27
5'-nucleotidase Inhibitors And Therapeutic Uses Thereof App 20160272643 - Chaloin; Laurent ; et al.	2016-09-22
Novel Chalcone Derivatives Having An Anti-allergic Activity App 20160052881 - DUMONTET; Charles ; et al.	2016-02-25
Combination Therapy Of A Type Ii Anti-cd20 Antibody With Increased Antibody Dependent Cellular Cytotoxity (adcc) App 20160000911 - DUMONTET; CHARLES ; et al.	2016-01-07
Use Of An Antibody And A Particulate Immunomodulator App 20140363500 - DUMONTET; Charles ; et al.	2014-12-11
Combination Therapy Of A Type Ii Anti-cd20 Antibody With Increased Antibody Dependent Cellular Cytotoxity (adcc) App 20140065134 - DUMONTET; CHARLES ; et al.	2014-03-06
Novel Azacoumarin Derivatives Having Mdr Pump Inhibiting Activity App 20140038883 - Doleans-Jordheim; Anne ; et al.	2014-02-06
Combination Therapy Of A Type Ii Anti-cd20 Antibody With Increased Antibody Dependent Cellular Cytotoxicity (adcc) App 20120301459 - Dumontet; Charles ; et al.	2012-11-29
Combination Of A Tlr3 Ligand And A Chemotherapy Agent Which Acts On The Intrinsic "apoptosis" Pathway In The Treatment Of Cancer App 20120045523 - Lebecque; Serge ; et al.	2012-02-23
Combination Therapy Of A Type Ii Anti-cd20 Antibody With Increased Antibody Dependent Cellular Cytotoxicity (adcc) App 20110177067 - Dumontet; Charles ; et al.	2011-07-21
Combination Therapy Of A Type Ii Anti-cd20 Antibody With Increased Antibody Dependent Cellular Cytotoxicity (adcc) App 20100310581 - Dumontet; Charles ; et al.	2010-12-09
Combination Therapy Of A Type Ii Anti-cd20 Antibody With Increased Antibody Dependent Cellular Cytotoxicity (adcc) App 20090246197 - DUMONTET; CHARLES ; et al.	2009-10-01
Novel Chalcone Derivatives With Antimitotic Activity App 20090182058 - Boumendjel; Ahcene ; et al.	2009-07-16

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.